Esophageal and Esophagogastric Junction Cancer

§  Systematic inclusion of cost-benefit analyses in clinical trial with collection of health economic analysis such as incremental cost effectiveness ratio in order to facilitate clinical decision-making. 

§  Predictive biomarkers: response to specific systemic targeted therapies and immunotherapy. 

§  Improve models for pre-clinical testing of novel drugs. 

§  Search for tools to assess quality of life and in clinical trials.

§  Dietary supplements, nutritional counselling, physical activity recommendations and psychological support as part of an integrative healthcare approach to care for people with esophageal cancer.